A phase II trial of Q3 week or weekly paclitaxel in combination with bevacizumab for metastatic or unresectable angiosarcoma

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: cc4f51d9e22ace75b68fd58abdee0ec2db84b835
First added on: Feb 08, 2025